TeacherWeb

Endocrinology - Hellerman



Top Divider


DM News Update

 
IM News Home Back Issue Archive Search User
Pref
Help Logout
Table of
Contents
Drug
Links
<<
Article
>>
Article

May 1 2002 • Volume 35 • Number 9

News

New definition based on heart risk
Hyperglycemia Starts at 90 mg/dL

Mitchel L. Zoler
Philadelphia Bureau


ATLANTA — The standard threshold for hyperglycemia may be too high.

People with a fasting serum glucose level of 100-125 mg/dL had an adjusted, 2.8-fold higher risk of having had a coronary heart disease event than people with a fasting glucose level of less than 79 mg/dL, in a cross-sectional study of 2,440 people, Dr. Dennis L. Sprecher said at the annual meeting of the American College of Cardiology.

A fasting serum glucose level of more than 125 mg/dL is the current threshold for identifying patients with diabetes. But the new finding suggests that patients with high levels of serum glucose in the nondiabetic range also face a substantial risk of having coronary heart disease.

At the Cleveland Clinic Foundation “we now use a fasting serum glucose of 90 mg/dL or higher as a biomarker of coronary heart disease risk,” said Dr. Sprecher, head of the foundation's section of preventive cardiology. “The cutoff of 125 mg/dL was based on the incidence of diabetic retinopathy,” but physicians now increasingly focus on the diabetes-related risk of coronary heart disease, he said. As evidence accumulates, the definition of diabetes may change.

The study participants were seen at the preventive cardiology clinic from January 1996 through February 2001. All had fasting serum glucose levels in the nondiabetic range. They had been referred to the clinic for treatment of lipid or blood pressure abnormalities, or for the prevention of coronary heart disease. The patients were judged to have existing coronary heart disease if they had a documented myocardial infarction; coronary catheterization showing more than 50% stenosis of a major coronary artery; a history of coronary bypass surgery or a percutaneous coronary procedure; or a functional cardiac study that showed coronary artery disease (such as a stress echocardiogram or a stress thallium examination). A total of 1,274 (52%) of these people had known coronary heart disease. Fasting serum glucose levels in these people ranged from 37 to 125 mg/dL, with a mean of 89 mg/dL, Dr. Sprecher said.

For this analysis, the study participants were divided into quintiles based on their fasting serum glucose level. The lowest quintile had levels of 79 mg/dL or less; the highest quintile had levels of 100-125 mg/dL. The multivariate analysis that examined the relationship between fasting serum glucose and coronary heart disease controlled for body mass index, the Framingham risk score, and nontraditional risk factors such as fibrinogen, homocysteine, and lipoprotein (a).

The absolute prevalence of coronary heart disease was 65% in the highest quintile and 43% in the lowest quintile. When the analysis controlled for all other risk factors, the men in the highest serum glucose quintile had a 2-fold higher risk of coronary heart disease, compared with the men in the lowest quintile. The women in the highest quintile had a 3.5-fold higher risk, compared with the women in the lowest quintile.

“We try to intervene with exercise, diet, and weight control.” These people may also be candidates for treatment with a drug such as metformin, he said.

“We now use a fasting serum glucose of 90 mg/dL or higher as a biomarker” of CHD risk, Dr. Dennis L. Sprecher said. Cleveland Clinic Foundation
fqm02035090101
Click on Image to view full size




Copyright © 2002 by International Medical News Group. Click for restrictions.

 

NEW YORK (Reuters) -Jan 2004: Four prominent medical organizations warned on Tuesday that a widely prescribed class of antipsychotic drugs increase the risk of diabetes, echoing concerns raised by U.S. regulators and researchers.

The American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists and the North American Association for the Study of Obesity joined forces in a statement published in the February issue of Diabetes Care.

The drugs, known as atypical antipsychotics, are used to treat a variety of mental illnesses, including schizophrenia, bipolar disorder, dementia, psychotic depression, autism and developmental disorders and generate more than $8 billion a year.

The panel of organizations said the drugs may increase the risk of obesity, diabetes and high cholesterol, all of which raise the chances of developing heart disease. The U.S. Food and Drug Administration in 2003 told makers of the drugs to include these risks in product labels. Few companies have complied.

This is the first time such a wide body of medical associations has formally expressed concern about the drugs. The move could potentially alter the relative market share of the drugs involved, which account for the bulk of a global schizophrenia medications market.

The market for atypical anti-psychotics is divided between six main products: Novartis AG's (NOVN.VX: Quote, Profile, Research) Clozaril; Johnson & Johnson's (JNJ.N: Quote, Profile, Research) Risperdal; Eli Lilly and Co.'s (LLY.N: Quote, Profile, Research) Zyprexa; AstraZeneca Plc's (AZN.L: Quote, Profile, Research) Seroquel; Pfizer Inc.'s (PFE.N: Quote, Profile, Research) Geodon; and Bristol-Myers Squibb Co.'s (BMY.N: Quote, Profile, Research) Abilify.

Zyprexa has annual sales of some $4 billion and accounts for about half Lilly's profit. The company said it is not clear whether there is a direct link between its drug and diabetes. AstraZeneca said the same about Seroquel. Pfizer and Bristol-Myers Squibb's drugs do not appear to have the same risks, doctors have said, though Pfizer's carries the risk of a condition that can lead to a potentially fatal heart arrhythmia.

The panel's report cited Zyprexa and Clozaril as the drugs most likely to increase the risk of weight gain, diabetes and lipid disorders.

© Reuters 2004. All Rights Reserved.


Bottom Divider



Printable Version

TeacherWeb

Last Modified: Tuesday January 27 2004

© 2001-2007 TeacherWeb, Inc.